Predictive Oncology (Predictive Oncology) Total Payout Ratio : 0.00 (As of Apr. 30, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Predictive Oncology's current Total Payout Ratio is 0.00.

Predictive Oncology Total Payout Ratio Historical Data

The historical data trend for Predictive Oncology's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Total Payout Ratio Chart

Predictive Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

0.29

0.38

2.60

0.26

Predictive Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Predictive Oncology's Total Payout Ratio

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Oncology's Total Payout Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Total Payout Ratio falls into.

Predictive Oncology Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Predictive Oncology's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-0.002	+	0	+	0)	/	-13.984
	=	-0.00

Predictive Oncology's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-3.475
	=	0.00

Predictive Oncology Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology (Predictive Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Executives

Robert L Myers	officer: CHIEF FINANCIAL OFFICER	4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr	director	633 1ST STREET WEST, SONOMA CA 95476
Veena Rao	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr	director	1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch	director	P O BOX 1572, PEPPERELL MA 01463
Pamela Bush	officer: Chief Business Officer	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley	director	1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith	director	151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle	director	1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz	10 percent owner	20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel	director	900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121